Home Featured

Featured

AveXis Inc (NASDAQ:AVXS): Of Course The FDA Didn’t Ask For Placebo Data

ME Contributor - November 3, 2016

Why the Performance of Sarepta Therapeutics Inc. (NASDAQ:SRPT) Eteplirsen Could Determine the Future of Drug Regulation

Highlighting ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) As A Catalyst Play This Quarter

Off the Radar Dermira Targets a Billion Dollar Opportunity

Here’s Why Capricor Therapeutics Inc (NASDAQ:CAPR) Is Running This Week

Trial Data Is Driving Gains In Kura Oncology, Inc. And (NASDAQ:KURA)...

ME Contributor - September 8, 2017

The Ups And Downs Of Novartis AG (ADR) (NYSE:NVS)’s Latest Approval

ME Contributor - May 30, 2017

Here’s A Near Term Opportunity In Oncology

ME Staff - October 16, 2015

Two Big Parkinson’s Updates From Adamas Pharmaceuticals Inc (NASDAQ:ADMS) And Acorda...

ME Contributor - August 5, 2016

Biotech Movers: Stemline Therapeutics, Inc. (NASDAQ:STML) And Mylan N.V. (NASDAQ:MYL)

ME Contributor - November 1, 2017

Two Biotechs With Bad News This Week: What Happens Now?

ME Contributor - September 15, 2016

Why Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) Climbed 23% This Week

Rafi Farber - August 19, 2016

Ebola Silver Bullet a Social Not Financial Win for Merck

Jennifer Aldershot - August 5, 2015

How NeuroRx Pharma is Turning Suicidal Ideation Into A Treatable Condition

David Rich - November 30, 2016

Biotech 101: Knowing Your Designations

Jennifer Aldershot - September 23, 2015

12 3...80 Page 1 of 80

EDITOR PICKS

Market Exclusive Daily Roundup, What You Need To Know April 18

April 18, 2018

Here’s What Happened Last Week In Biotech

April 17, 2018

ArQule, Inc. Is Moving On ASCO Release, Here’s Why.

April 16, 2018

Weekly Biotech Report covering – Opko Health Inc (NYSE:OPK) Intercept...

April 11, 2016

Facebook Inc – (NASDAQ:FB) Might Be Moving Away From Its...

April 8, 2016

Biotechnology Movers: Here’s Why Citius Pharmaceuticals Inc (NASDAQ:CTXR) Is Running Right...

November 8, 2017

ABOUT US

Market Exclusive offers the latest financial news and analysis for selected US stocks and securities. We are an investor driven research platform where new investment ideas from a exclusively selected group of seasoned investment analysts and qualified members from various disciplines are able to deliver their investment thesis’ across various industries and sectors. Our burgeoning team is comprised of individuals with strong backgrounds from various disciplines and businesses. Our goal is to provide an exclusive forum for contributors and users to leverage the knowledge base in order to make smarter investing decisions. At Market Exclusive, we believe that quality information from experienced well seasoned contributors provide our members with an edge that allows them to make wise investment choices. Market Exclusive is not a registered investment broker/dealer. The content on this site is for informational purposes only. Additionally, the content on this site does not represent the views of Market Exclusive and is solely a representation of the authors who publish them. Before investing in any security you should do your own due diligence and consult with a registered broker or financial advisor.